Heard on the Street: Pharmaceutical companies are opting to make smaller biotech acquisitions. That’s great news for biotech stocks. https://t.co/Xja6zlaX6L ...

Gilead Sciences agrees to buy private German biotech Tubulis in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development, sources say https://t.co/KRZYp5EQv0 ...

Good morning. It is 5 a. m.in New York City, 10 a. m. in London.I'm Matt Miller in for Vonnie Quinn. And I've got a stick mic today because apparently the lav mic isn't working. This is Bloomberg brief.Let's get you set up for the day. We are looking at stock futures that are up as oil fluctuates and US allies rush for a cease fire, a ceasefire deal with Iran that says President Trump's new yet again delayed deadline looms for Tehran to reopen the Strait of Hormuz. If you're following along, it is now 8 p.m ...

Anthropic buys biotech startup Coefficient Bio in $400M deal: reports https://t.co/RO725N6uJk ...

🚨 JUST IN: Anthropic has acquired biotech startup Coefficient Bio for approximately $400 million, per The Information. https://t.co/XMwo3cSYHv ...

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the pricing of a best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants t ...

Core Viewpoint - Resverlogix Corp. is currently under a management cease trade order application due to delays in completing its annual financial statements audit, which has resulted in a default on the filing deadline [1][2]. Group 1: Management Cease Trade Order (MCTO) Update - The application for the MCTO is still under review by the Alberta Securities Commission (ASC), with no decision made yet [1]. - The company has defaulted on the March 31, 2026 deadline for filing its annual audited financial statements and related documents due to the auditor's inability to complete the audit on time [1][2]. - The company is working with the auditor to resolve initial delays and is optimistic about completing the annual filings by April 10, 2026, although this cannot be assured [2]. Group 2: Implications of the Default - If the MCTO is granted, the CEO and CFO will be prohibited from trading the company's securities, while the general public can continue trading the company's common shares [3]. - The company is committed to satisfying the alternative information guidelines under NP 12-203, including issuing bi-weekly default status reports until the annual filings are completed [4]. Group 3: Company Background - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company specializing in epigenetics and aims to develop first-in-class therapies for chronic diseases [6]. - The company is focused on its lead epigenetic candidate, apabetalone, for treating cardiovascular disease and related conditions [7]. - Resverlogix's common shares are traded on the Toronto Stock Exchange under the ticker RVX [8].

Core Insights - The stock market experienced a significant rally, closing near session highs on the last trading day of March, driven by optimism surrounding a potential U.S.-Iran truce and portfolio repositioning by fund managers at the end of the first quarter [1][2]. Group 1: Market Performance - The Nasdaq composite surged by 3.8%, marking a notable performance on the first trading day of the month [1]. - The overall market rally was influenced by President Trump's comments regarding a potential exit from the Iran conflict, even with the Strait of Hormuz remaining closed [2]. Group 2: Sector Highlights - Chip and biotech stocks led the market gains, indicating strong investor interest in these sectors amid the broader market rally [1]. - Marvell's stock saw a significant increase due to its investment and partnership with Nvidia, highlighting the positive sentiment in the tech sector [3].

Financial Data and Key Metrics Changes - The company reported approximately $22.3 million in cash and current assets after accounting for liabilities at year-end [38] - Operating expenses were about $10 million, with a cash burn of $5.7 million for the year [39] - Post spin-out of the clearing platform and PatentVest, operating expenses are expected to decrease to about $6 million annually, enhancing financial leverage [40][41] Business Line Data and Key Metrics Changes - MDB Capital has successfully launched 18 IPOs, with all but the most recent trading at significant premiums to their IPO prices, indicating strong market positioning [6] - The company has invested around $4 million annually in MDB Direct and PatentVest since going public, establishing them as distinct assets with independent value [20][37] Market Data and Key Metrics Changes - The company is focusing on the public venture market, which is increasingly appealing to individual investors rather than traditional institutional investors [24] - The market for patent prosecution in the U.S. is estimated to be between $10 billion and $15 billion, presenting a significant opportunity for growth [30] Company Strategy and Development Direction - The company aims to scale its operations to launch 3-5 companies per year, leveraging AI to streamline processes and reduce time to market [11][18] - MDB Capital is exploring strategic partnerships to monetize its clearing operations and enhance distribution capabilities [23][25] Management's Comments on Operating Environment and Future Outlook - Management acknowledges macroeconomic risks and challenges in the microcap market, but remains optimistic about the potential for portfolio companies to execute successfully [42][43] - The company is confident in its ability to generate significant equity value from its current assets, with all principal assets having billion-dollar potential [41][49] Other Important Information - The company is in the process of developing AI-driven tools to enhance its operational efficiency and reduce the time required for due diligence [12][14] - MDB Capital is planning to take POLX public later this year, with expectations for significant clinical trial results that could impact its valuation [35][36] Q&A Session Summary Question: Can you talk about Q, ClearSign, and Beat? Also, what about Buda? - ClearSign is on a long commercialization journey with promising prospects due to its unique burner technology [52] - HeartBeam has achieved FDA approval for a groundbreaking ECG device, which could save millions of lives [53] - Buda is positioned to lead in the fresh juice market, capitalizing on a global shift towards fresh products [56] Question: What is the outlook for eXoZymes regarding dilution? - eXoZymes has a capital-efficient model with minimal expected dilution due to its focus on significant market opportunities [61][62] Question: How will the spin-out of PatentVest impact shareholders? - Both MDB Direct and PatentVest are fully owned by the company, and the goal is to secure funding and take them public by 2027 [64][65] Question: What does the deal pipeline look like for the next 12-24 months? - The company anticipates a strong deal pipeline but emphasizes the need to enhance distribution capabilities to successfully sell these opportunities [66][67] Question: Have you considered a SaaS model for PatentVest? - The company believes that AI will significantly disrupt the SaaS model, as it can perform tasks more efficiently than traditional methods [70][74]

Financial Data and Key Metrics Changes - The company reported a cash burn of approximately $5.7 million for the year, with fixed operating expenses around $10 million [38][39] - After accounting for investments in clearing operations and PatentVest, the effective cash burn was reduced to $1.7 million [39] - The company anticipates a significant reduction in operating expenses to about $6 million annually post spin-out of its clearing platform and PatentVest [39][41] Business Line Data and Key Metrics Changes - MDB Capital Holdings has successfully launched 18 IPOs, with all but one trading at a significant premium to their IPO prices, indicating strong market performance [6] - The company aims to scale its operations to launch 3-5 companies per year, enhancing its impact and portfolio for investors [5][41] Market Data and Key Metrics Changes - The company has been investing approximately $4 million annually in MDB Direct and PatentVest, which are seen as valuable independent assets [20][37] - The market for patent prosecution in the U.S. is estimated to be between $10 billion and $15 billion, presenting a significant opportunity for growth [30] Company Strategy and Development Direction - The company is focusing on leveraging AI to enhance its operational efficiency and reduce the time required to prepare companies for public offerings, potentially compressing timelines from months to weeks [11][18] - MDB Capital Holdings is exploring strategic partnerships to monetize its clearing operations and PatentVest, aiming for a public offering in 2027 [62] Management's Comments on Operating Environment and Future Outlook - The management expressed optimism about the future, citing the potential for all four principal assets to achieve billion-dollar valuations [48] - Concerns were raised about macroeconomic risks and the challenges faced by microcap companies in the current market environment [42] Other Important Information - The company is in discussions to spin out its clearing operations and PatentVest as independent entities, which are expected to enhance shareholder value [62] - The management highlighted the importance of addressing distribution challenges to successfully launch new companies [66] Q&A Session Summary Question: Can you talk about ClearSign, HeartBeam, and Buda? - ClearSign is on a commercialization journey with promising prospects. HeartBeam has received FDA approval for a groundbreaking ECG device, while Buda is positioned to lead in the fresh juice market, capitalizing on a growing consumer trend [50][51][54] Question: What is the outlook for eXoZymes regarding dilution? - eXoZymes is expected to have minimal dilution due to its capital-efficient operations and significant opportunities in NCT and cannabinoids [58][60] Question: How will the spin-out of PatentVest impact shareholders? - Both MDB Direct and PatentVest are wholly owned by the company, and the goal is to secure funding and take them public, which could provide significant value to shareholders [62] Question: What does the deal pipeline look like for the next 12-24 months? - The company anticipates a strong deal pipeline but emphasizes the need to solve distribution challenges to successfully launch new companies [64][66] Question: How does the company view the SaaS model for PatentVest? - The management believes that SaaS will be overshadowed by AI advancements, as AI can significantly enhance the efficiency of patentability analysis [68][70]